Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 1, 2008, Pages 9-16

  Prakash, Om ^a   Medhi, Bikash ^a   Saikia, Uma Nahar ^a   Pandhi, Promila ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; MALONALDEHYDE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DESCENDING COLON; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; MALE; MORPHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SCORING SYSTEM; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MALONDIALDEHYDE; PEROXIDASE; RATS; RATS, WISTAR; SULFASALAZINE; THALIDOMIDE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 45749116085     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00240.x     Document Type: Article

References (24)

1. Fridman S, Blumberg RS. Inflammatory bowel disease. In : Braunwald E, Fauci AS, Kasper DL, Hanser SL, Longo DL, Jameson JL (eds). Harrison's Principle of Internal Medicine, 16th edn, vol. 2. McGraw Hill, New York, 2005 1679 92.
2. Kenneth M, Mc Quid MD. Alimentary tract. In : Tierney LM, Macphee SJ, Papadakis MA (eds). Current Medical Diagnosis and Treatment, 42th edn. McGraw Hill, New York, 2003 602 11.
3. Palmer KR, Penman ID. Disease of the alimentary tracts and pancreas. In : Haslett C, Chilvers ER, Hunter JA, Boon NA (eds). Davidson's Principle and Practice of Medicine, 18th edn. Churchill Livingstone, Edinburgh, UK, 1999 659 68.
4. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of it's mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996 35 : 969 79.
5. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human peripheral blood mononuclear cells stimulated with concanavallin-A, staphylococcus enterotoxin-A and purified protein derivatives. Immunopharmacology 1995 31 : 160 7.
6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Anti-tumour activity of thalidomide in refractory multiple myeloma. N Eng J Med 1999 341 : 1565 71.
7. Jacobson J, Greenspan J, Spritzler J, Ketter N, Fahey JL, Jackson JB et al. Thalidomide for the treatment of oral apthous ulcer in patients with human immunodeficiency virus, National Institute of Allergy and Infectious disease AIDS Clinical Trial Group. N Eng J Med 1997 336 : 1487 93.
8. Gerhard VH, Wolfgang GJ. Experimental colitis. In : Drug Discovery and Evaluation Pharmacological Assay, 2nd edn, Springer, Berlin, Germany, 2002 896 9.
9. Levine A, Kenet G, Bruk R, Avni Y, Avinoach I, Aeed H et al. Effect of heparin on tissue binding activity of fibroblast growth factor and heparin binding epidermal growth factor in experimental colitis in rats. Pediatric Res 2002 51 : 635 40.
10. Krawiesz JE, Sharan P, Stenson WF. Quantitative assay to acute intestinal inflammation based on myeloperoxidase activity: assessment of inflammation in rats and hamster model. Gastroenterology 1984 87 : 1344 50.
11. Ohkawa H, Ohishi N, Yoge K. Assay of lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem 1978 95 : 351 8.
12. Lehmann C, Egerer K, Georgiew A, Weber M, Grune T, Kox WJ et al. Inhibition of TNF-α release in rat experimental endotoximia by treatment with 21 aminosteroid U-74389G. Crit Care Med 1999 27 : 1164 7.
13. Morris GP, Rebeiro L, Herride MM, Szewczuk M, Depew W. An animal model of chronic granulomatous inflammation of stomach and colon. Gastroenterology 1985 86 : 1188.
14. Ward M. The pathogenesis of Crohn's disease. Lancet 1977 11 : 903 5.
15. Shorter RG, Huizenga KA, Spencer RJ. A working hypothesis for etiology and pathogenesis of nonspecific inflammatory bowel disease. Am J Dig Dis 1972 17 : 1024 32.
16. Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP. Elevated plasma leptin concentration in early stages of experimental intestinal inflammation in rats. Gut 1998 43 : 783 90.
17. Ko JKS, Lam FYL, Cheung APL. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J Gastroenterol 2005 11 : 5787 94.
18. Saiki T. Myeloperoxidase concentration in the stool as a new parameter of inflammatory bowel disease. Kurume Med J 1998 45 : 69 73.
19. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury:role of reactive oxygen metabolites. Dis Dig Sci 1988 33 : 6s 15s.
20. Riddel RH. Pathology of idiopathic inflammatory bowel disease. In : Kirsner JB, Shorter RG (eds). Inflammatory Bowel Disease. Lea and Febiger, Philadelphia, PA, 1988 329 50.
21. Branhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on anti-inflammatory properties of thalidomide effect of on PMN leukocyte and monocytes. J Am Acad Dermatol 1984 11 : 814 9.
22. Muller C. Tumour necrosis factor in mouse models of chronic intestinal inflammation. Immunonology 2002 105 : 1 8.
23. Alexander-Williams J. Historical review. In : Allan RN, Rhodes JM, Hanauer SB (eds). Inflammatory Bowel Disease. Churchill Livingstone, Edinburgh, UK, 1997 3 10.
24. Radomsky CL, Levine N. Thalidomide. Dermatol Clin 1997 336 : 1487 93.